Although neurotrophins elicit both acute and long-term effects, it is unclear whether the two modes of action are mediated by the same or different mechanisms. Using neuromuscular junction (NMJ) as a model system, we identified three characteristic features required for long-term, but not acute, forms of synaptic modulation by neurotrophin-3 (NT-3): endocytosis of NT-3-receptor complex, activation of the PI3 kinase substrate Akt, and new protein synthesis. Long-term effects were eliminated when NT-3 was conjugated to a bead that was too large to be endocytosed or when dominant-negative dynamin was expressed in presynaptic neurons. Presynaptic inhibition of Akt also selectively prevented NT-3-mediated long-term effects. Blockade of protein translation by the mammalian target of rapamycin inhibitor rapamycin prevented the long-term structural and functional changes at the NMJ, without affecting the acute potentiation of synaptic transmission by NT-3. These results reveal fundamental differences between acute and long-term modulation by neurotrophins.
Introduction
Neurotrophins, a family of structurally and functionally related proteins that include nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5(NT-4/5), have recently emerged as major regulatory factors for synapse development and plasticity (McAllister et al., 1999; Poo, 2001; Lu, 2003) . Recent studies indicate that synaptic actions of neurotrophins can be divided into two temporally distinct modes: acute effect occurring within seconds or minutes after exposure to a neurotrophin and long-term effects taking hours and days to accomplish (Lu, 2004) . In addition, the acute actions of neurotrophins are often associated with the strengthening of preexisting synapses, whereas long-term ones involve formation of new synaptic connections. For example, at cultured Xenopus neuromuscular synapses, acute application of a neurotrophin elicits a rapid and transient enhancement of synaptic transmission that requires continuous presence of the factors (Lohof et al., 1993) . In contrast, long-term treatment with the same neurotrophin induces a profound change in synaptic efficacy that persists even after withdrawal (Wang et al., 1995) .
Furthermore, long-term treatment with NT-3 elicits a series of morphological changes that include axonal arborization and synaptic growth (Wang et al., 1995) . In hippocampal slices, acute application of BDNF facilitates early phase long-term potentiation (Figurov et al., 1996) , but long-term treatment with BDNF increases synapse number and spine density in dendrites of pyramidal neurons, together with modulation of synaptic efficacy (Tyler and Pozzo-Miller, 2001; Ji et al., 2005) .
Although the acute and long-term synaptic effects by neurotrophins have been widely observed, little is known about molecular mechanisms underlying these two temporally distinct modes. Initial signaling events by the two modes may be similar. Binding of a neurotrophin to a specific Trk receptor induces its tyrosine kinase activity, leading to the activation of kinase pathways, including phosphatidylinositol 3-kinase (PI3K), mitogenactivated protein (MAP) kinase, and phospholipase C-␥ (PLC-␥) (Kaplan and Miller, 2000; Huang and Reichardt, 2003) . Unlike other growth factors, internalization of the neurotrophin-Trk receptor complex (endocytosis) triggers signaling events that are quite different from those occurring on the cell surface, thereby mediating unique biological functions of neurotrophins (Riccio et al., 1997; Watson et al., 1999; York et al., 2000; Zhang et al., 2000; Watson et al., 2001) .
Studies that examine the molecular mechanisms underlying synaptic actions of neurotrophins have been hampered primarily by difficulties in altering gene expression at presynaptic and postsynaptic sites, particularly for synapses in the CNS. To overcome these difficulties, we used the Xenopus neuromuscular synapses, in which specific gene products can be expressed selectively presynaptically or postsynaptically. Here, we demonstrate at least three important factors that distinguish the acute and long-term effects of NT-3: endocytosis of NT-3-receptor complex, activa-fluorescent images of FM-dye were acquired by a MicroMax 1300 cool CCD camera (Roper Scientific, Trenton, NJ) mounted on an Olympus IX70 inverted epifluorescence microscope and analyzed off-line using IPLab software (Scanalytics, Fairfax, VA) . Fluorescence images were taken with 1000 ms exposure time with a 40ϫ, 0.55 numerical aperture (NA) objective. The pseudocolor (green) was assigned to fluorescent images, and the superimposed Hoffman optics and fluorescence images were created by the IPLab software. FM-dye destaining experiments were performed as described previously (Ryan et al., 1993) with minor modification. In brief, FM 1-43 was loaded into neurons as described above for 3 min, and cells were washed extensively with Ringer's solution. Fluorescence images were acquired at a rate of 0.2 Hz with 250 ms exposure time with a 25ϫ, 0.4 NA objective. After acquiring five images (10 s) as a baseline, FM 1-43 destaining was initiated by rapid perfusion of high K ϩ loading solution (60 mM KCl, 57.6 mM NaCl, 2.0 mM CaCl 2 , 10 mM HEPES, pH 7.6). The image data were stored and analyzed off-line by IPLab software. Fluorescence intensities were extracted from time-lapse images of individual boutons. The data were normalized to background fluorescence, fitted by single exponential curves, and time constants () were obtained and averaged.
Quantification of FM-dye fluorescence image. Each pixel in a fluorescent image contains intensity information that follows a normal distribution around the peak intensity. To obtain the number of fluorescence spots, an arbitral threshold is usually placed on fluorescent signals across the entire image, and the number of spots that pass this intensity threshold was counted. However, this analysis cannot be used to accurately measure the intensity information. To quantify the intensity of fluorescent spots, a common way is to use the same size of windows or region of interests (ROIs) on each fluorescent spot (Ryan et al., 1996) . This analysis, although revealing the true intensity value for each is to fluorescent signal, is difficult to obtain the true number of the fluorescent spots. To truthfully reflect the changes in the number as well as the intensity of the fluorescent varicosity and yet to avoid cumbersome data presentation, we used a morphological index that combined two quantification measurements with equal weights (morphological index, 0.5 ϫ number of fluorescent spot per unit length of axon ϩ 0.5 ϫ average fluorescence intensity of fluorescent spots in axon) (McAllister et al., 1995) . To measure the number of fluorescent spots, we first calculated background intensity by averaging intensities from three nonfluorescent areas along the axon. To eliminate nonspecific fluorescent signals, a fluorescent spot was considered as a "varicosity" only when the following criteria were met: (1) its average fluorescent intensity was higher than 100% above the background; and (2) its size was larger than 0.5 m in diameter. By using the ROI tool in the IPLab program, the number of fluorescent spots in the axon and the length of neuronal process were calculated in a semiautomated way. The number of fluorescent spots in 100 m was calculated by the following formula: total number of spots/total length of axon ϫ 100 m ϭ the density of fluorescent spots. To measure unbiased average intensity of the fluorescent spots, we first measured the optical center of mass of a given fluorescent spot. Then, we placed the same size of ROI (0.5 ϫ 0.5 m) to the center of mass of each fluorescent spot and measured the intensity of each spot. Then, measured intensity of spots in a single neuron were pooled and averaged. Student's t test was used for statistical analysis.
Western blotting. Xenopus embryos at stage 20 were quickly homogenized in extraction buffer (100 mM NaCl, 50 mM Tris-HCl, pH 7.5, 1% NP-40, 2 mM PMSF, 1 g/ml aprotinin, 1 g/ml leupeptin, 1 g/ml pepstatin A, 2 M Na 3 VO 4 ) and subsequently sonicated. High-speed centrifugation produced an insoluble pellet that was discarded. Supernatants were transferred to a fresh tube containing 300 l of Freon (1,1,2-trichlorotrifluoroethane) (Sigma) vortexed for 1 min, incubated on ice for 5 min, and centrifuged again to remove yolk protein. The protein concentrations of the supernatants were determined using the Bio-Rad (Hercules, CA) protein assay. The proteins were separated by SDSpolyacrylamide electrophoresis and blotted onto Immobilon-P membrane (Millipore, Bedford, MA). The blots were probed with primary antibodies (anti-HA for Dynamin, 1:200; anti-c-myc for PI3K or Akt, 1:300), followed by a secondary antibody conjugated with HRP. Signals were detected by chemiluminescence kit (Pierce, Rockford, IL).
Immunofluorescence microscopy. Xenopus nerve-muscle cultures were treated with or without pharmacological drugs for 30 min at room temperature before NT-3 application. The cultures were fixed 30 min after NT-3 application by using 4% paraformaldehyde (EM Science, Gibbstown, NJ) for 30 min at room temperature and washed three times with 0.1 M NaBH 4 (sodium borohydrate) in PBS to reduce autofluorescence. Fixed cells were permeabilized with 0.1% Triton X-100 in PBS for 5 min. Fixed cells were blocked with 5% BSA and incubated with primary antibodies against phospho-Akt 1:100 (polyclonal; Cell Signaling Technology, Beverly, MA) or phospho-ribosomal S6 protein 1:200 (polyclonal; Cell Signaling Technology) overnight at 4°C. Secondary antibodies were Alexa 546 (Invitrogen). Fluorescent images were captured with an Olympus (Tokyo, Japan) IX70 microscope using a CCD camera, acquired with IPLAb software and processed with Adobe Photoshop (Adobe Systems, San Jose, CA). For statistical analysis, Ͼ70 neurons (see Fig. 7 ) or Ͼ20 neurons (supplemental Fig. 4 , available at www.jneurosci.org as supplemental material) from at least three different experiments were measured. The 2 test was used to determine the level of significance. Preparation of NT-3-bead. Generation of NT-3-beads is based on a noncovalent but very tight binding interaction between streptavidin and biotin. To biotinylated NT-3 in mild physiological condition, FluoReporter Biotin-XX protein labeling kit was used (Invitrogen). Briefly, 100 g of NT-3 was diluted with 200 l of distilled water and 20 l of 1 M sodium bicarbonate (0.84 g of NaHCO 3 in 10 ml of distilled water; pH 8.4) was added. Two microliters of reactive form of Biotin-XX and sulfosuccinimidyl ester sodium salt were added into a reaction tube that contained NT-3 in bicarbonate solution and incubated for 2 h at room temperature. After biotinylation, NT-3-biotin was collected and purified by a spin column. Approximately 80 -90% of biotinylated NT-3 is recovered after column centrifugation. The biological activity of NT-3-biotin was accessed by electrophysiological recording. To quantify biotinylated NT-3, we measured the protein concentration of biotin-labeled NT-3 by analyzing the absorbance at 280 nm using a NanoDrop spectrophotometer (Nanodrop Technology, Wilmington, DE), because biotin does not absorb at 280 nm. Then, the number of biotin labels on a protein was determined by using the biotin quantification assay kit (Invitrogen). To make NT-3-bead, 100 l of streptavidin beads (1.25% w/v; Bangs Laboratories, Fisher, IN) with binding capacity of 7.5 mol biotinylated conjugates per 1 l of bead were rinsed three times with PBS, centrifuged, and resuspended in 100 l of 0.1 M PBS, pH 7.4. To this, 100 g of freshly made NT-3-biotin was added and allowed to mix on a rotary shaker overnight (12-14 h) at 4°C. NT-3-beads were centrifuged and rinsed three times to remove any unbound NT-3-biotin. The pelleted NT-3-beads resuspended in 100 l of 0.1 M PBS and stored at 4°C until use. To quantify amounts of NT-3 on NT-3-bead, we deduced the approximate concentration of NT-3 biotin from the number of beads per milliliter (2.5 ϫ 10 11 particles/ml) and the amounts of proteins bound. NT-3 bound to each bead was estimated to be 0.30 Ϯ 0.05 pg (n ϭ 3). By electrophysiological measurement, we found that 2 l of beads in PBS (30 ng of NT-3 bead) was enough to induce acute synaptic potentiation in a single neuron. Therefore, we set this concentration comparable with 50 ng/ml NT-3. For long-term experiments, we used 0.2 l of beads, which is 10 times lower, to cover each neuron. To test the strength of bond between NT-3-biotin and avidin-beads, 5 l of NT-3 beads was vortexed for 30 s and spun for 5 min. Then, the free NT-3 in the supernatant was measured by NT-3 E max Immunoassay system (Promega, Madison, WI). In three independent experiments, the concentration of NT-3 in the supernatant was lower than the detection level of the kit (Ͻ Ͻ10 pg/ml).
Protein synthesis inhibition assay. We used destabilized EGFP vector (pd1EGFP-N1; Clontech, Cambridge, UK) to monitor the inhibition of new protein synthesis. In this vector, residues 422-461 of mouse ornithine decarboxylase (MODC) were fused to the C terminus of EGFP, and this region of MODC contains a PEST amino acid sequence that targets the protein for degradation and results in rapid protein turnover. This PEST amino acid sequence of MODC is highly conserved in Xenopus, mice, and humans and correlated with most short-lived proteins. pd1EGFP has a half-life of ϳ1 h, as measured by fluorescence intensity of cells treated with the protein synthesis inhibitor cycloheximide (Li et al., 1998) . pd1EGFP was expressed in Xenopus spinal neurons by embryo injection. pd1EGFP-associated fluorescence for a given neuronal soma was calculated by subtracting the fluorescence intensity in background area (representing no-cell area) from the averaged intensity of three different areas. Each image was collected with time-lapse fluorescence microscopy. Average fluorescence intensity was calculated for a region of interest containing a single neuronal soma. The dimensions of each region of interest were six pixels by six pixels (1.0 ϫ 1.0 m). Regions of interest were initially positioned by the eye and corrected for the center of mass of each soma by an automated script in IPLab. Initial average intensity from three frames was considered as 100% fluorescence intensity and fluorescence intensity from each frame was normalized to correct for possible changes in gain between experiments. Drugs (rapamycin, 200 nM) (Biomol, Plymouth meeting, PA) were added 30 min before timelapse recording, and no adverse morphological change was observed after drug treatment.
Results

Physiological and morphological changes at NMJ induced by long-term treatment with NT-3
At the Xenopus neuromuscular synapses, application of exogenous NT-3 at a high concentration (50 ng/ml) induces a rapid potentiation of synaptic transmission within 5 min (Lohof et al., 1993) , whereas long-term treatment with NT-3 (50 ng/ml; 2 d) facilitates physiological and morphological maturation of the synapses (Wang et al., 1995) . To determine whether simple extension of NT-3 incubation would convert the acute to long-term effects, or the two temporally different modes of NT-3 actions operate by different mechanisms, we used a low concentration (5 ng/ml) of NT-3. At this concentration, NT-3 did not elicit acute synaptic potentiation. No physiological change was observed even when the cells were treated with NT-3 for 1 h at this concentration. The frequency of SSCs 1 h after NT-3 treatment was 97.2 Ϯ 21.3% of that of control (n ϭ 6; p Ͼ 0.6; t test). Thus, a lower dose of NT-3 did not merely delay the timing of an acute response. In contrast, long-term treatment (2 d) at this concentration resulted in a marked increase in synaptic efficacy at the neuromuscular synapses. The frequency and amplitude of SSCs were 5.2 Ϯ 1.8 events/min and 310 Ϯ 34 pA in untreated synapses (n ϭ 11) but 13.4 Ϯ 2.7 events/min and 489 Ϯ 71 pA in NT-3-treated synapses (n ϭ 13; p Ͻ 0.01 for SSC frequency; p Ͻ 0.05 for ESC amplitude; t test). All recordings of SSCs were done in the presence of TTX (1 M), and therefore the increase was not a result of firing of action potentials or increase in neuronal excitability.
To determine whether these changes occur in a synapsespecific manner, we expressed NT-3 gene in postsynaptic muscle cells by embryo injection techniques (Wang et al., 1995) . Synaptic activities were compared in a triplet system in which a spinal neuron innervated two myocytes, one of which expressed exogenous NT-3 (as indicated by GFP fluorescence) (Fig. 1 A) . The whole-cell recording was made on both myocytes in the triplet. The frequency (events/min) of SSCs was 5.8 Ϯ 1.7 from control synapses (myocytes not expressing NT-3, or M-) but 14.3 Ϯ 2.4 in NT-3-expressing synapses (Mϩ) (n ϭ 13 in both; p Ͻ 0.02; t test), suggesting that NT-3 increased transmitter release by approximately twofold to threefold (Fig. 1 B) . There was no change in SSC amplitude (469 Ϯ 57 pA in M-synapses and 465 Ϯ 60 pA in Mϩ synapses; p Ͼ 0.7; t test). It is unclear why postsynaptic NT-3 expression was less effective than bath application of NT-3 in changing SSC amplitude. Because the postsynaptic effect of NT-3 was relatively small, we focused our analysis on the SSC frequency.
The amplitude of ESCs, elicited by stimulating presynaptic somata of spinal neurons, was also higher at synapses treated with exogenous NT-3 for 2 d (Fig. 1C) . The amplitude of ESCs were 1746 Ϯ 253 pA from myocytes not expressing NT-3 but 3263 Ϯ 310 pA from NT-3-expressing myocytes (n ϭ 8; p Ͻ 0.01). The rise time and decay time of ESCs were not changed (data not shown). The changes in spontaneous and evoked synaptic activities suggest that long-term postsynaptic expression of NT-3 could enhance synaptic efficacy by regulating presynaptic neurotransmitter release properties.
Next, we examined whether acute or long-term treatment with NT-3 induces any morphological change indicative of more mature synapses. Similar to cultured hippocampal neurons (Baranes et al., 1996) , the axons of Xenopus spinal neurons exhibited "morphological varicosities" (Fig. 2 A) that contain clusters of synaptic vesicles as well as other presynaptic elements necessary for exocytosis and endocytosis. It has been shown that in developing neurons, membrane recycling is not limited to the nerve terminal but occurs in the entire axonal surface, particularly at the varicosities (Sun and Poo, 1987; Evers et al., 1989; Dai and Peng, 1996) , and spontaneous transmitter secretion along the axonal shaft is strikingly similar to that in the terminals (Chang and Popov, 1999) . Moreover, synaptic varicosities have been shown to serve as synaptic boutons at the NMJ of Drosophila larvae and Caenorhabditis elegans in vivo (Davis et al., 1998; Zhao and Nonet, 2000) . Thus, the number and the size of the varicosities may reflect the maturation of neurotransmitter release capacity.
To effectively reveal synaptic varicosities, we used the FM dye staining technique (Betz et al., 1992; Ryan et al., 1993; Wang et al., 2002) . Cultures were exposed to high K ϩ (60 mM) solution for 3 min in the presence of FM 1-43 (2 M). Such depolarization elicited a massive vesicle fusion, followed by a rapid internalization of FM 1-43 dye, which labels all recycling synaptic vesicles. As shown in Figure 2 A, strong fluorescent spots, which reflect clusters of FM-dye loaded vesicles, were observed along the axons of spinal neurons in all cultures. Synaptic varicosities are defined as morphological spots with fluorescence intensity two times or more than background and larger than 0.5 m in diameter. Treatment of the neurons with NT-3 significantly increased the number (control, 0.69 Ϯ 0.10 spot/100 m; NT-3, 1.70 Ϯ 0.22 spot/100 m; p Ͻ 0.02), as well as the average fluorescent intensity (control, 2.00 Ϯ 0.08 fluorescence unit; NT-3, 2.45 Ϯ 0.07 fluorescence unit; p Ͻ 0.01) of the FM dye spots (Fig. 2 A) . Because the changes in the number and the intensity usually went in parallel, we used a morphology index (morphological index, 0.5 ϫ number of fluorescent spot per unit length of axon ϩ 0.5 ϫ average fluorescence intensity of fluorescent spots in axon) for the assessment of FM dye spot (Fig. 2 B) (see Materials and Methods). In contrast, acute application of NT-3 did not result in any morpho- logical change (data not shown). Thus, long-term exposure to NT-3 may facilitate the formation of synaptic vesicle clusters and increase the numbers of release sites.
To confirm that these FM dye-labeled varicosities truly reflect synaptic release sites, we performed FM dye destaining experiments. Figure 2C shows the images of a spinal neuron loaded with FM 1-43. Strong fluorescence was observed in the synaptic varicosities. Transmitter release was initiated by rapid perfusion of high K ϩ destaining solution containing the same [Ca 2ϩ ] o (2 mM) as the wash solution. More than 90% of the dye fluorescence disappeared within 2 min after the perfusion of high K ϩ destaining solution (Fig. 2 D) (supplemental movie, available at www. jneurosci.org as supplemental material). The time constant () was 43.2 Ϯ 4.2 s in control neurons (n ϭ 16) and 29.8 Ϯ 5.3 s in neurons treated with NT-3 for 2 d (n ϭ 13; p Ͻ 0.04; t test). We also analyzed destaining kinetics from FM dye-labeled spots within postsynaptic myocytes, which presumably serve as sites for synaptic vesicle release. The time constant was 57.4 Ϯ 8.2 s in control synapses (n ϭ 9) and 28.4 Ϯ 5.6 s in synapses treated with NT-3 for 2 d (n ϭ 7; p Ͻ 0.05; t test). These data are consistent with the changes in SSC frequency. Together, these results suggest that long-term exposure to NT-3 not only enhances transmitter release but also promotes the morphological differentiation of the synaptic boutons.
Requirement of endocytosis of NT-3 receptor complex in NT-3-mediated long-term synaptic effects
After binding and activation of the Trk receptors, the neurotrophin-receptor complex gets endocytosed (Grimes et al., 1996) . To determine whether the endocytosis of NT-3-receptor complex is necessary for acute and/or long-term synaptic modulation, we introduced two forms of Dynamin I in spinal neurons through embryo injection. Dynamin I is the GTPase required in the final step of endocytosis. We used DN Dynamin I, in which lysine 44 is replaced with glutamate (K44E), to block endocytosis. Western blot analysis revealed the expression of either HA-tagged WT or DN-Dynamin in 2-d-old embryos, suggesting that the injected mRNAs remained intact at the time of electrophysiological recording (Fig. 3A) . In 1-d-old cultures, acute application of NT-3 elicited a marked increase in transmitter release in neurons expressing DN-Dynamin (Fig. 3B) . Thus, inhibition of endocytosis does not affect the acute modulation of transmission by NT-3. In contrast, expression of DN-Dynamin in presynaptic neurons completely blocked the enhancement of synaptic efficacy induced by long-term exposure to NT-3 (Fig. 3C) . In DNDynamin-expressing synapses, the SSC frequency was 3.14 Ϯ 0.5 events/min in the absence of NT-3 (n ϭ 11), but NT-3 treatment no longer increased SSC frequency (3.7 Ϯ 0.52 events/min; n ϭ 19; p Ͼ 0.5; t test). Expression of WT-Dynamin did not prevent the potentiating effect of NT-3 (control, 5.7 Ϯ 0.8 events/min; NT-3, 12.8 Ϯ 0.9 event/min; p Ͻ 0.05; t test) (Fig. 3C) . Moreover, expression of DN-Dynamin in the postsynaptic muscle cells (N-Mϩ) had no effect on NT-3-induced synaptic potentiation (control, 5.8 Ϯ 0.7 events/min; NT-3, 13.8 Ϯ 0.6 events/min; p Ͻ 0.05; t test) (Fig. 3C) . Almost identical results were obtained using the amplitude of ESCs to measure synaptic efficacy. Expression of DN-Dynamin in presynaptic neurons completely prevented the potentiating effect of NT-3 on ESC amplitude (control, 855 Ϯ 147 pA; NT-3, 635 Ϯ 176 pA; p Ͼ 0.4; t test) (Fig. 3D) . These results support the notion that endocytosis of NT-3-TrkC complex in presynaptic neurons is important for NT-3-induced longterm, but not acute, synaptic modulation.
One may argue that DN-Dynamin could also affect the endocytosis of vesicles for neurotransmitter or factors other than NT-3; therefore, expression of DN-Dynamin prevented the effect of NT-3. Indeed, there was a small but significant reduction (30 -40%) in basal SSC frequency (control, 6.1 Ϯ 0.6 event/min; DNDynamin, 3.1 Ϯ 0.5 events/min; p Ͻ 0.05) and ESC amplitude (control, 1746 Ϯ 253 pA; DN-Dynamin, 855 Ϯ 147 pA; p Ͻ 0.05) recorded in untreated DN-Dynamin-expressing neurons (Fig.  3C,D) . Two experiments were performed to address this concern. First, we reasoned that if the expression of DN-dynamin affects the general well being of transmitter release properties, then the acute synaptic modulation by NT-3 should not occur in 2-d-old culture. However, the acute effect persisted even in neurons expressing DN-Dynamin for 2 d (supplemental Fig. 2 B, available at www.jneurosci.org as supplemental material), suggesting that inhibition of endocytosis for 2 d does not alter the basic transmitter release properties. Second, we tested the acute and long-term effects of NT-3-biotin-avidin conjugated beads (NT-3-beads) that were too large (Ͼ1 m in diameter) to be internalized into neurons or muscle cells (Fig. 4 A) . Briefly, recombinant NT-3 was biotinylated (NT-3-biotin) and incubated with avidin-conjugated beads (Avidinbead), which was conjugated with cyanine 3 and therefore emitted a red fluorescence. Unbound biotinylated NT-3 was removed by extensive washes. The bond between NT-3-biotin and avidinbeads should be extremely tight and, therefore, there should be no free or biotinylated NT-3. To test this, 5 l of NT-3 beads were vortexed for 30 s and spun for 5 min. In three independent experiments, the free NT-3 in the supernatant, measured by ELISA, was lower than detection level (Ͻ10 pg/ml).
Both acute and long-term effects of the NT-3-beads were tested. Two microliters of NT-3-bead (30 ng) were sufficient to induce maximal acute potentiation (Fig. 4 B) . For long-term treatment, we used one-tenth of the amount used for acute effect or 3 ng (0.2 l of NT-3 beads in PBS) of NT-3 beads. Interestingly, long-term treatment of the cultures with the NT-3-beads no longer elicited any change in synaptic efficacy (control, 5.9 Ϯ 0.7 events/min; NT-3 bead, 4.4 Ϯ 0.4 events/min; p Ͼ 0.2; t test) (Fig. 4C) . As controls, treatment with NT-3-biotin induced similar magnitude of synaptic potentiation as NT-3 alone (10.9 Ϯ 0.9 events/min; p Ͻ 0.05; t test), and treatment with avidin-beads had no effect (4.8 Ϯ 0.8 events/min) (Fig. 4C) . Moreover, NT-3-beads did not induce any long-term change in synaptic varicosities (Fig. 4 D) . It was also noted that the biological activity of the NT-3 conjugated beads was stable over 2 d in culture medium at room temperature. Together, endocytosis of the NT-3-receptor complex is required for the long-term physiological and morphological development of the neuromuscular synapse.
Critical role of Akt in NT-3-mediated long-term synaptic effects
We have demonstrated previously that activation of PI3K and PLC-␥ signaling pathways is both necessary and sufficient to mediate the acute synaptic potentiation induced by NT-3 (Yang et al., 2001 ). To test whether PI3K is also involved in long-term modulation of NMJ by NT-3, we applied 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002; 5 M) (Vlahos et al., 1994) , a specific inhibitor of PI3K. Although this inhibitor did not produce any change at control synapses, cotreatment with NT-3 and LY294002 for 2 d blocked NT-3-induced synaptic potentiation in terms of SSC frequencies (control, 5.6 Ϯ 1.0 events/ min; LY294002, 6.1 Ϯ 1.2 events/min; NT-3, 13.7 Ϯ 1.7 events/ min; LY294002 with NT-3, 5.0 Ϯ 1.0 events/min) (Fig. 4 A) . Treatment with another PI3K inhibitor, wortmannin (100 nM) (Powis et al., 1994) , also prevented the NT-3-induced increase in SSC frequency (data not shown). In contrast, inhibition of MAP kinase pathway by either 2Ј-amino-3Ј-methoxyflavone (PD098059) (10 M) (Alessi et al., 1995) or 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126) (10 M) (Zhu et al., 2002) did not abolish the NT-3-induced increase in SSC frequency (U0126, 5.3 Ϯ 0.6 events/min; PD098059, 5.2 Ϯ 7.8 events/min; U0126 with NT-3, 13.1 Ϯ 1.6 events/min; PD098059 with NT-3, 14.6 Ϯ 1.0) (Fig. 5A) . Treatment with Xestospongin C (XeC) (1 M) (Gafni et al., 1997) , a specific inhibitor for IP 3 receptor, also had no effect on NT-3-induced synaptic potentiation (XeC, 6.4 Ϯ 1.0 events/min; XeC with NT-3, 14.3 Ϯ 0.8 events/min). Thus, unlike the acute effect, the long-term modulation of NMJ development by NT-3 requires the activation of one of the three Trk signaling pathways, the PI3K pathway. To investigate the locus of PI3K action, we expressed dominant-negative PI3K (DnPI3K) in either presynaptic spinal neurons or postsynaptic myocytes using the embryo injection techniques as described previously (Yang et al., 2001) . Expression of DnPI3K in presynaptic neurons, but not in the postsynaptic myocytes, completely blocked the synaptic potentiation by NT-3 on both SSC frequency (control, 3.1 Ϯ 0.3 events/ min; NT-3, 3.1 Ϯ 0.4 events/min) (Fig. 5C ) and ESC amplitude (control, 1188 Ϯ 165 pA; NT-3, 1239 Ϯ 141 pA) (Fig. 5D ). Similar to the physiological effects, inhibition of PI3K by LY294002 also blocked the change in synaptic varicosities induced by longterm treatment with NT-3 (Fig. 5B) . These results suggest that both physiological and morphological changes induced by NT-3 are mediated by activation of PI3K in presynaptic spinal neurons.
A major downstream target of PI3 kinase is the serine/threonine kinase Akt. We have previously shown that Akt at the presynaptic spinal neurons could be activated by NT-3 treatment (Yang et al., 2001 ). Here, we tested whether Akt is required for NT-3-induced synaptic potentiation using embryo injection techniques. Western blot analysis showed the expression of Myctagged wild-type and dominant-negative-Akt [Myc-WT-Akt and Myc-DN-Akt (K179M), respectively] in Xenopus neural tubes 2 d after embryonic mRNA injection (Fig. 6 A) . To test whether Myc-DN-Akt successfully inhibits Akt signaling, we performed immunocytochemistry using an antibody against the phosphorylated form of S6 (pS6), a ribosomal protein downstream of Akt signaling. At least 20 neurons were examined in each condition, and consistent results were obtained. Approximately 34% (9 of 26) of cells were positive for pS6 immunostaining under control conditions. Application of NT-3 increased pS6 by ϳ65% (15 of 23) (between with NT-3 and without NT-3; p Ͻ 0.05; 2 test) (supplemental Fig. 4 , available at www.jneurosci.org as supplemental material). Expression of Myc-DN-Akt in Xenopus spinal neurons attenuated the NT-3-induced S6 phosphorylation: ϳ33% (7 of 21) of cells were positive for pS6 (EGFP vs EGFPϩDN-Akt, p Ͼ 0.8; EGFP with NT-3 vs EGFPϩDN-Akt with NT-3, p Ͻ 0.05; EGFPϩDN-Akt vs EGFPϩDN-Akt with NT-3, p Ͼ 0.9; 2 test) (supplemental Fig. 4 , available at www.jneurosci.org as supplemental material). Neurons expressing GFP alone or noninjected control neurons still exhibited an increase in pS6 when treated with NT-3 (supplemental Fig. 4 B, C , available at www.jneurosci. org as supplemental material).
Expression of Myc-DN-Akt, but not Myc-WT-Akt, in presynaptic neurons completely blocked the long-term synaptic potentiation by NT-3 on SSC frequency (DN-Akt, 2.6 Ϯ 0.7 events/ min; DN-Akt with NT-3, 2.7 Ϯ 0.8 events/min; WT-Akt, 6.0 Ϯ 1.9 events/min; WT-Akt with NT-3, 12.0 Ϯ 2.9 event/min) (Fig.  6C) . Expression of Myc-DN-Akt in postsynaptic myocytes had no effect on these synapses (data not shown). These results suggest that expression of Myc-WT-Akt alone does not produce an enhancement of long-term synaptic efficacy. Surprisingly, presynaptic expression of Myc-DN-Akt did not prevent the potentiation of synaptic transmission induced by acute application of NT-3 ( p Ͻ 0.01; t test) (Fig. 6 B) . Thus, although both require PI3K, a major difference in the signaling mechanisms is that longterm, but not acute, synaptic modulation by NT-3 depends on the target of PI3K, Akt.
NT-3-mediated long-term synaptic modulation requires protein synthesis
Akt is a key factor controlling protein synthesis. NT-3-induced activation of Akt results in phosphorylation and activation of the mTOR protein, leading to the initiation of protein translation (Raught et al., 2001) . To test whether protein synthesis is a hallmark that sets long-term modulation by NT-3 apart from its acute effect, we used drugs that blocked protein synthesis. The two widely used protein synthesis inhibitors, anisomycin and cycloheximide, appeared to be toxic to the nerve-muscle cultures 2 d after treatment (data not shown). In contrast, 2 d treatment with rapamycin (200 nM), a specific inhibitor for mTOR, did not show any toxic effects on cultured cells (supplemental Fig. 2 F, available at www.jneurosci.org as supplemental material). Because of a limited number of cells available in these nerve-muscle cocultures (ϳ30 neurons per culture dish), it was not feasible to directly measure protein synthesis using conventional approaches, such as 3 H-leucine incorporation. We therefore used two alternative approaches to measure the efficacy of rapamycin in blocking protein synthesis. First, we measured the activity of S6 kinase, an mTOR target that phosphorylates ribosomal S6 protein. Immunostaining using an anti-pS6 antibody revealed that treatment with NT-3 elicited a marked increase in pS6 in spinal neurons: ϳ38% (33 of 86) of cells were positive for pS6 immunostaining without treatment and 76% (86 of 113) of cells were positive after treatment with NT-3; p Ͻ 0.01, 2 test) (Fig. 7 A, B) . This increase was severely attenuated when the cells were pretreated with rapamycin for 1 h, whereas treatment with rapamycin alone slightly reduced the basal levels of pS6: ϳ30% (19 of 64) of cells were positive for pS6 immunostaining with rapamycin and 43% (39 of 90) of cells were positive with rapamycin and NT-3 (Fig. 7B) . Second, we used an unstable GFP (pd1-EGFP; half life, 1 h), the fluorescence of which fades when protein synthesis is blocked. The residues 422-461 of mouse ornithine decarboxylase (MODC) were fused to the C terminus of EGFP. This region of MODC contains a PEST sequence that targets proteins for degradation, leading to a rapid protein turnover (Li et al., 1998) . When pd1-EGFP was expressed in spinal neurons by embryo injection, treatment of the cultures with rapamycin (200 nM) or cycloheximide (60 M) for 1 h greatly reduced fluorescence intensity as a result of the inhibition of new EGFP synthesis (Fig. 8 A) (Mateus and Avery, 2000) . These results confirm rapamycin successfully blocked de novo protein synthesis in Xenopus spinal neurons.
When nerve-muscle cocultures were incubated with NT-3 and rapamycin together for 2 d, the long-term effects of NT-3 on the neuromuscular synapses were abolished. As shown in Figure  8C , SSC frequencies exhibited no increase in synapses treated with rapamycin and NT-3 together (rapamycin, 3.6 Ϯ 0.5 events/ min; rapamycin with NT-3, 3.5 Ϯ 0.4 events/min; p Ͼ 0.1; t test). Treatment with rapamycin alone slightly reduced the basal SSC frequency compared with control synapses (control, 5.9 Ϯ 0.7 events/min; rapamycin, 3.6 Ϯ 0.5 events/min) (Fig. 8C) . Similarly, treatment with rapamycin prevented the increase in synaptic varicosities induced by long-term treatment with NT-3 without affecting the basal level of synaptic varicosity (Fig. 8 D) . In contrast, treatment with rapamycin did not affect acute potentiation of synaptic transmission elicited by 1 d or even 2 d of treatment with NT-3 (Fig. 8 B) (supplemental Fig. 3E , available at www.jneurosci.org as supplemental material). Together, these data suggest that new protein synthesis is required for long-term, but not acute, synaptic effects of NT-3. To confirm that the effects of rapamycin were not attributable to nonspecific, pharmacological effects, we performed a similar analysis of SSCs, ESCs, and synaptic morphology using rapamycin at a 10 times lower concentration (20 nM). Even at this concentration, rapamycin still successfully blocked both physiological (supplemental Fig. 3A-C , available at www.jneurosci.org as supplemental material) and morphological (supplemental Fig. 3D , available at www.jneurosci. org as supplemental material) effects by long-term treatment with NT-3.
Discussion
Recent studies have identified neurotrophins as an important class of regulatory factors for synaptic development and plasticity. A major insight from previous studies is that neurotrophins regulate synapses in two temporally distinct modes: acute regulation of synaptic transmission and plasticity that occurs in a time scale of seconds or minutes, and long-term effects on synaptic structures and function that take days to accomplish (Lu, 2004) . A number of pressing questions remain to be addressed. What are the hallmarks for the acute and long-term effects other than their temporal differences? Are two modes of actions mediated by similar or different mechanisms? We identified three characteristic features that are required for long-term, but not acute, forms of synaptic modulation by NT-3: endocytosis of neurotrophinreceptor complex, activation of Akt, and new protein synthesis. Our study provides the first systematic characterization of the mechanistic differences between two modes of neurotrophic regulation based on their distinct molecular mechanisms rather than purely on the temporal scales of their actions.
Role of protein synthesis
Our study suggests that one of the fundamental differences between acute-and long-term forms of synaptic modulation by neurotrophins is the requirement for protein translation. To support this notion, we used rapamycin to inhibit mTOR, a kinase that phosphorylates 4E binding protein and dissociates translation factor eukaryotic initiation factor 4E. Bath application of rapamycin blocks both the physiological as well as the morphological effects induced by long-term treatment with NT-3. However, the acute effects elicited by NT-3 were not blocked by rapamycin. Consistent with this, a previous study showed that acute potentiation of synaptic transmission elicited by NT-3 is not blocked by the protein synthesis inhibitor anisomycin or cycloheximide (Chang and Popov, 1999) .
NT-3-induced protein synthesis could occur in soma, presynaptic terminals, or both. Using a triplet system in which a bifurcated motor neuron innervating two postsynaptic muscle cells, one of which expressing NT-3, we found that the long-term synaptic potentiation occurred only at the NT-3-expressing synapse (Fig. 1 A) . Similar synapse-specific long-term effects were observed in a triplet system expressing NT-4 (Wang et al., 1998) . These results raise the possibility that protein synthesis required for the long-term synaptic effects induced by neurotrophins occurs locally in the presynaptic terminals. Indeed, localized synaptic potentiation by BDNF has been shown to depend on local protein synthesis in the developing axons (Zhang and Poo, 2002) . In Aplysia, local protein synthesis is thought to be a key mechanism for synapse-specific long-term facilitation induced by serotonin (Martin et al., 1997) . Additional studies are necessary to determine whether such local protein synthesis contributes to the synapse specificity of neurotrophic regulation.
Role of Akt
Although Akt is highly expressed in the CNS and is known to mediate diverse biological responses, the role of Akt in synaptic modulation has not been adequately addressed. The present study provides physiological evidence that Akt is selectively involved in long-term, but not acute, synaptic modulation. What does Akt do to contribute selectively to the long-term synaptic modulation by NT-3? Activation of PI3K occurs at the plasma membranes, whereas activated Akt acts in the cytoplasm. The cytoplasmic targets of Akt, therefore, should be considered as candidates mediating the long-term synaptic effects of NT-3. Because expression of dominant-negative Akt did not appear to affect the survival of spinal neurons (H.-S.J. and B.L., unpublished observation), it is less likely that conventional targets of Akt such as Bcl-2-associated death protein, Forkhead, or nuclear factor B are involved (Huang and Reichardt, 2003) . In contrast, substantial evidence indicates that Akt activates a number of effectors involved in protein synthesis (Whiteman et al., 2002; Harris and Lawrence, 2003) . A major effector of Akt is mTOR, a kinase that triggers initiation of translation. Overexpression of a membrane targeted Akt in mammalian cells increase mTOR kinase activity as well as mTOR autophosphorylation (Scott et al., 1998; Sekulic et al., 2000) . Another effector of Akt is glycogen synthase kinase-3␤ (GSK-3␤). Akt-mediated phosphorylation and inactivation of GSK-3␤ increases the exchange activity of the guanine nucleotide exchange factor eIF-2B and promotes the recruitment of initiator tRNA to the 40S ribosome. Together, it is conceivable that Akt acts as a signaling molecule that links upstream NT-3 signals to the key effectors that control protein synthesis necessary for long-term physiological and morphological changes at the NMJ.
Role of receptor endocytosis
Endocytosis has long been considered as a mechanism to inactivate receptor-signaling process, but recent studies suggest that, unlike other tyrosine kinase receptors, the endocytosis of neurotrophin-Trk complexes is necessary for several biological effects mediated by neurotrophins (Lu, 2004; Nagappan and Lu, 2005) . For example, TrkA endocytosis is required to initiate cell body responses to target-derived NGF; blockade of TrkA internalization by dominant-negative Dynamin prevents NGFinduced neurite outgrowth in PC12 cells (Bhattacharyya et al., 1997; Riccio et al., 1997; Zhang et al., 2000) . In the present study, we demonstrate that endocytosis of NT-3-receptor complex represents one of the key mechanisms that separate the acute and long-term synaptic effects of NT-3.
Then, why is endocytosis necessary for long-term, but not acute, effects of NT-3? Or more generally, are there fundamental differences between cell surface and endocytosed receptors in terms of their signaling and functions? It has been shown that epidermal growth factor induces proliferation through a transient activation of MAP kinase, whereas NGF induces differentiation via a sustained activation of the same signaling pathway (Marshall, 1995) . NT-3 may activate transient signaling when interacting with cell surface TrkC but more sustained signaling when endocytosed together with its receptor TrkC. Another possibility is that cell surface and endocytosed TrkC receptors activate totally different signaling pathways. NGF activates Ras through cell surface TrkA, leading to a transient activation of MAP kinase, but Rap1 through endocytosed TrkA, resulting sustained MAP kinase (York et al., 2000) . Inhibition of receptor endocytosis attenuates MAP kinase activation but increases PI3K signaling (Zhang et al., 2000) . Consistent with this, binding of surface TrkA by NGF-beads activates PI3K normally but not MAP kinase (MacInnis and Campenot, 2002) . In PC12 cells, the activated NGF-Trk complex is endocytosed into coated vesicles called signaling endosomes (Howe et al., 2001) . The extracellular domain of the receptor, now inside the lumen of the vesicles, remains bound to NGF, whereas the intracellular domain of Trk is kept in the phosphorylated state and is catalytically active. This allows its association with signal-generating proteins such as Shc, Rap1, PLC-␥, etc. (Howe et al., 2001) . In addition to the differences in kinetics and downstream signaling molecules, endocytosis takes the receptor to different intracellular locations and makes it less exposed to surface membrane-associated phosphatases. All together, these mechanisms could contribute to the differential signaling between cell surface and endocytosed receptors. It is also conceivable that internalized NT-3-TrkC complexes may be able to differentially activate downstream signaling pathways by using intracellular endosomes, thereby separating the acute and long-term effects of the same neurotrophin.
Our data strongly suggest that a key difference between acute and long-term effects of NT-3 on synaptic modulation is the dependence on NT-3-TrkC endocytosis. However, it should be noted that the concentration of NT-3 used to examine the longterm effect of NT-3 was 20 times lower than that used for the acute effect. We used such a low dose of NT-3 to selectively induce signaling pathways for the long-term effect and therefore distinguish it from the acute effect. As such, however, we cannot completely rule out the possibility that differential dependence on endocytosis may reflect dose rather than time of NT-3 exposure.
Conclusion
Here, we showed distinct mechanisms that separate two temporarily different actions of neurotrophins by using simple and unique system. These mechanistic differences could be applicable to the neurotrophic regulation of CNS synapses (Lu, 2004) . For example, recent studies indicate that long-term neurotrophic treatment of mammalian hippocampal neurons induce dendritic morphological changes (Tyler and Pozzo-Miller, 2001; Ji et al., 2005) . Furthermore, several recent studies have demonstrated that BDNF induces PI3K/mTOR-dependent protein synthesis in dendrites of CNS neurons (Schratt et al., 2004; Takei et al., 2004) . Some findings such as the requirement for endocytosis of receptors in neurotrophin-mediated long-term synaptic modulation are not established in activity-dependent long-term plasticity. Therefore, it will be interesting to investigate whether similar mechanism is operative in long-term activity-dependent synaptic modulation. In conclusion, these findings, if generalized to other neurotrophic factors, should have a significant impact not only in the understanding of how neurotrophic factors work in the brain but also in the therapeutic application of neurotrophins as drugs for various neurological disorders.
